|
Status |
Public on Sep 03, 2022 |
Title |
GGGR 01S-07 |
Sample type |
protein |
|
|
Source name |
Pancreatic cancer
|
Organism |
Homo sapiens |
Characteristics |
sample group: GGGR tissue: Blood
|
Extracted molecule |
protein |
Extraction protocol |
Protein was extracted from plasma using a protein extraction buffer (Fullmoon Biosystems, Sunnyvale, CA) and protein expression was analyzed using antibody microarray analysis (Fullmoon Biosystems) according to the manufacturer’s protocol.
|
Label |
Biotin/Cy3-Streptavidin
|
Label protocol |
50ug of protein sample was labeled and incubated with coupling mixture on the antibody microarray slide (Fullmoon Biosystems).
|
|
|
Hybridization protocol |
protein sample was detected with Cy3-streptavidin (GE Healthcare, Chalfont St. Giles, UK).
|
Scan protocol |
The slide was rinsed scanned using the GenePix 4100A scanner (Axon Instrument, USA) at 10 um resolution, optimal laser power and PMT.
|
Description |
01S-07-Visit 1
|
Data processing |
Following image scanning, they were gridded and quantified with GenePix 7.0 Software (Axon Instrument, USA). Normalized signal is calculated from average intensity of replicate spots / median signal.
|
|
|
Submission date |
Sep 01, 2022 |
Last update date |
Sep 03, 2022 |
Contact name |
Jung Hyun Jo |
E-mail(s) |
junghyunjo83@gmail.com
|
Organization name |
Yonsei University Health System
|
Street address |
50-1 Yonsei-ro
|
City |
Seoul |
State/province |
--- Select --- |
ZIP/Postal code |
120-752 |
Country |
South Korea |
|
|
Platform ID |
GPL32338 |
Series (1) |
GSE212575 |
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomized, phase 3 trial. |
|